1. Drug‐Induced Liver Injury in GI Practice
- Author
-
Naemat Sandhu and Victor J. Navarro
- Subjects
Drug ,Liver injury ,medicine.medical_specialty ,Hepatology ,Clinical events ,business.industry ,media_common.quotation_subject ,MEDLINE ,Liver failure ,Review ,medicine.disease ,Epidemiology ,medicine ,lcsh:Diseases of the digestive system. Gastroenterology ,lcsh:RC799-869 ,Intensive care medicine ,business ,media_common - Abstract
Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug‐related and herbal and dietary supplement–related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management., Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. DILI is also the most common single adverse event that has led to withdrawal of drugs from the marketplace, drug attrition, and failure of implicated drugs to obtain Food and Drug Administration approval. The development of various drug injury networks have played a vital role in expanding our knowledge regarding drug‐related and herbal and dietary supplement–related liver injury. In this review, we discuss what defines liver injury, epidemiology of DILI, its biochemical and pathologic patterns, and management.
- Published
- 2020